.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Julphar
Cerilliant
Citi
Covington
Cipla
Baxter
Johnson and Johnson
Argus Health
US Army
Harvard Business School

Generated: February 21, 2018

DrugPatentWatch Database Preview

Patents Expiring in 2033

« Back to Dashboard

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Silvergate PharmsXATMEPmethotrexate sodiumSOLUTION;ORAL208400-001Apr 25, 2017RXYesYes➤ Sign Up➤ Sign UpY
Silvergate PharmsXATMEPmethotrexate sodiumSOLUTION;ORAL208400-001Apr 25, 2017RXYesYes➤ Sign Up➤ Sign UpY
Astrazeneca PharmsEPANOVAomega-3-carboxylic acidsCAPSULE;ORAL205060-001May 5, 2014RXYesYes➤ Sign Up➤ Sign UpY
Astrazeneca PharmsEPANOVAomega-3-carboxylic acidsCAPSULE;ORAL205060-001May 5, 2014RXYesYes➤ Sign Up➤ Sign UpTREATMENT OF HYPERTRIGLYCERIDEMIA
Celgene CorpIDHIFAenasidenib mesylateTABLET;ORAL209606-002Aug 1, 2017RXYesYes➤ Sign Up➤ Sign UpYYTREATMENT OF RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH AN ISOCITRATE DEHYDROGENASE-2 (IDH2) MUTATION
Celgene CorpIDHIFAenasidenib mesylateTABLET;ORAL209606-001Aug 1, 2017RXYesNo➤ Sign Up➤ Sign UpYYTREATMENT OF RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH AN ISOCITRATE DEHYDROGENASE-2 (IDH2) MUTATION
Eyevance PharmsZERVIATEcetirizine hydrochlorideSOLUTION/DROPS;OPHTHALMIC208694-001May 30, 2017RXYesYes➤ Sign Up➤ Sign UpY
Vanda Pharms IncHETLIOZtasimelteonCAPSULE;ORAL205677-001Jan 31, 2014RXYesYes➤ Sign Up➤ Sign UpTREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY ORALLY ADMINISTERING 20MG OF TASIMELTEON ONCE DAILY BEFORE BEDTIME
Vanda Pharms IncHETLIOZtasimelteonCAPSULE;ORAL205677-001Jan 31, 2014RXYesYes➤ Sign Up➤ Sign UpTREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY ADMINISTERING TASIMELTEON
Vanda Pharms IncHETLIOZtasimelteonCAPSULE;ORAL205677-001Jan 31, 2014RXYesYes➤ Sign Up➤ Sign UpTREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER
This preview shows a limited number of results
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Mallinckrodt
Cipla
Farmers Insurance
Johnson and Johnson
Fuji
Covington
US Department of Justice
Citi
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2018 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot